New starch-based radiotracer for lung perfusion scintigraphy

Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):146-55. doi: 10.1007/s00259-009-1226-6.

Abstract

Purpose: In order to avoid the microbiological risks linked to human serum albumin macroaggregates (MAA) used for lung perfusion scintigraphy, we developed a new starch-based Tc-99m potential radiopharmaceutical.

Methods: Microparticles were prepared from oxidised starch coupled to natural polyamine for Tc-99m complexation. Suspensions were formulated as ready-to-use kits for easy one-step labelling procedures.

Results: Particle-size analysis, electron microscopy, and confocal microscopy were performed for microparticle characterisation, and gave a typical size distribution ranging from 7 to 63 microm, with a homogenous population of spherical or oval-shaped microparticles. Radiochemical purity exceeded 95%, and was stable for at least 8 h. When challenged with histidine and human plasma, labelling was also stable. Dynamic scintigraphic acquisitions and biodistribution studies conducted on healthy Wistar rats showed a tracer accumulation with more than 80% of the ID in the lungs after 15 min.

Conclusions: With clinically significant characteristics such as a lung half-life of 3 h, a lung-to-vascular ratio of 900, and a lung-to-liver ratio of 90, starch-based microparticles exhibit all the qualities for an effective new lung perfusion agent.

MeSH terms

  • Animals
  • Drug Carriers / chemistry
  • Isotope Labeling / methods
  • Lung / diagnostic imaging*
  • Lung / metabolism*
  • Male
  • Particle Size
  • Pattern Recognition, Automated / methods*
  • Perfusion Imaging / methods
  • Radiopharmaceuticals / chemical synthesis
  • Radiopharmaceuticals / pharmacokinetics*
  • Rats
  • Rats, Wistar
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Starch / chemistry*
  • Technetium / chemistry
  • Technetium / pharmacokinetics*

Substances

  • Drug Carriers
  • Radiopharmaceuticals
  • Technetium
  • Starch